Stent thrombosis in the era of drug-eluting stents;Die stentthrombose im fokus von drug-eluting stents

Herz

Volumn 32, Issue 5, 2007, Pages 411-418

  Wöhrle, Jochen ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Drug eluting stent; Myocardial infarction; Stent thrombosis

Indexed keywords

ANTITHROMBOCYTIC AGENT; PACLITAXEL; RAPAMYCIN;

ANGIOCARDIOGRAPHY; BRACHYTHERAPY; CORONARY ARTERY THROMBOSIS; CORONARY RISK; DRUG ELUTING STENT; ENDOTHELIUM CELL; HUMAN; IN-STENT RESTENOSIS; PATIENT SELECTION; PREDICTION; PRESCRIPTION; REVIEW;

BLOOD VESSEL PROSTHESIS; CLINICAL TRIALS; CORONARY THROMBOSIS; DRUG IMPLANTS; FEMALE; HUMANS; MALE; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; STENTS;

EID: 34548422749     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-007-2891-5     Document Type: Review

References (58)

1. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1967-71.
2. Malenka DJ, O'Rourke D, Miller MA, et al. Cause of in-hospital death in 12,232 consecutive patients undergoing percutaneous transluminal coronary angioplasty. Am Heart J 1999;137:632-8.
3. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
4. Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006;113:1108-13.
5. Schühlen H, Kastrati A, Dirschinger J, et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 1998;98:104-11.
6. Uren NG, Schwarzacher SP, Metz JA, et al. Predictors and outcomes of stent thrombosis. An intravascular ultrasound registry. Eur Heart J 2002;23:124-32.
7. Cheneau E, Leborgne L, Mintz GS, et al. Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study. Circulation 2003;108:43-7.
8. Brodie BR, Cooper C, Jones M, et al. Is adjunctive balloon postdilatation necessary after coronary stent deployment? Final results from the POSTIT trial. Cathet Cardiovasc Interv 2003;59:184-92.
9. Fujii K, Carlier SG, Mintz GS, et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol 2005;45:995-8.
10. Wenaweser P, Dörffler-Melly J, Imboden K, et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005;45:1748-52.
11. Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005;46:1827-32.
12. Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122-6.
13. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006;47:27-33.
14. Kotani J, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006;47:2108-11.
15. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
16. Virmani R. DES safety is suspect: animal and autopsies don't lie. DES Revolution 2006, Atlanta (www.tctmd.com).
17. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701-5.
18. Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006;47:175-81.
19. Finn AV, Kolodgie FD, Harnek J, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005;112:270-8.
20. Morice MC, Bestehorn HP, Carrié D, et al. Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents. The randomized JUPITER II trial. EuroIntervention 2006;2:45-52.
21. Weisz GW, Leon MB, Holmes DR, et al. Two-year outcomes after sirolimus-eluting stent implantation. J Am Coll Cardiol 2006;47:1350-5.
22. Morice MC, Colombo A, Meier B, et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions - the REALITY trial. JAMA 2006;295:895-904.
23. Meredith IT. Trial updates & long term follow-up - ENDEAVOR I: 3-year, ENDEAVOR II: 2-year clinical results. PCR 2006, Paris (www.europcronline.com).
24. Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions - clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006;114:798-806.
25. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
26. Meredith IT, Ormiston J, Whitbourn R, et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I trial. EuroIntervention 2005;1:157-64.
27. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005;294:1215-23.
28. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
29. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-9.
30. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-9.
31. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989-97.
32. Leon MB. Late thrombosis a concern with drug-eluting stents. J Interv Cardiol 2007;20:26-9.
33. TCT Daily. ESTROFA: late thrombosis not increased in DES patients. J Interv Cardiol 2007;20:32
34. Serruys PW. Early and late stent thrombosis with drug-eluting stents. TCT 2005, Washington (www.tctmd.com).
35. Hoye A, Iakovou I, Ge L, et al. Long-term outcomes after stenting of bifurcation lesions with the "Crush" technique: predictors of an adverse outcome. J Am Coll Cardiol 2006;47:1949-58.
36. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006;355:1093-104.
37. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006;355:1105-13.
38. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-21.
39. Wenaweser P, Rey C, Eberli FR, et al. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J 2005;26:1180-7.
40. Wang F, Stouffer GA, Waxman S, et al. Late coronary stent thrombosis: early vs. late stent thrombosis in the stent era. Cathet Cardiovasc Interv 2002;55:142-7.
41. Bavry AA, Kumbhani DJ, Helton TJ, et al. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention? A meta-analysis. J Am Coll Cardiol 2005;45:941-6.
42. Moreno R, Fernández C, Hernández R, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005;45:954-9.
43. Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006;98:352-6.
44. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006;113:2803-9.
45. Mintz GS. Intravascular ultrasound in the drug-eluting stent era. J Am Coll Cardiol 2006;48:421-9.
46. Moses J. DES revisited: current limitations and futuristic platforms. CIT 2006, Beijing (www.tctmd.com).
47. Stone GW. 2-year clinical results of the TAXUS IV trial. TCT 2004, Washington (www.tctmd.com).
48. Farb A, Boam AB. Stent thrombosis redux - the FDA perspective. N Engl J Med 2007;356:984-7.
49. Stone GW. DES evidence-based medicine. TCT 2006, Washington (www.tctmd.com).
50. Carlsson J, Reinius P, Muhr T, et al. Ist die späte Stentthrombose bei medikamentenbeschichteten Stents ein tatsächliches klinisches Problem? Clin Res Cardiol 2006;95:Suppl 5:P704.
51. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-78.
52. Kaiser C, Brunner-La Rocca HP, Buser PT, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet 2005;366:921-9.
53. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-91.
54. Mehta SR, Yusuf S, Peters RJG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
55. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005;26:804-47.
56. Stone GW. TCT 2006: Safety of paclitaxel-eluting stents: what have we learned thus far? TCT 2006, Washington (www.tctmd.com).
57. Silber S, Böhm M, Gottwik M, et al. Positionspapier der DGK zur koronaren Stentimplantation. Vermeidung von Tod und lebensbedrohlichen Komplikationen durch zusätzliche Gabe von Clopidogrel. Herz 2006;31:83-4.
58. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. J Am Coll Cardiol 2007;49:734-9.